Summary: Researchers have launched the first clinical trial at the University of Southern California to study psilocybin-assisted therapy paired with structured mindfulness meditation. The study will test whether an eight-week mindfulness program can enhance and prolong the therapeutic effects of psilocybin by measuring behavioral, physiological, and neural changes over time.
Approximately 72 healthy, psychedelic‑naive, middle‑aged adults from the Los Angeles area will take part in a randomized, eight‑week protocol. Participants will be assigned to receive supervised psilocybin-assisted therapy alone or psilocybin combined with a systematic mindfulness training program. Both groups will be monitored with an extensive battery of biological, physiological, cognitive, and neuroimaging assessments.
The multidisciplinary team will collect longitudinal data — including fMRI, EEG, blood, saliva, and stool microbiome samples — to map biological pathways linked to self-processing, inflammation, and neural plasticity. The goal is to identify objective markers and mechanistic signatures that could inform personalized, rapid‑acting behavioral health interventions.
Key Facts
- USC’s Psychedelic Debut: This is the first psychedelic-assisted therapy study conducted at the University of Southern California, marking a new institutional focus on pioneering mental health research.
- The Mindfulness Synergy: Investigators propose that mindfulness meditation supplies cognitive strategies to weaken maladaptive personal narratives, and that these strategies may be more effectively established when combined with psilocybin.
- ARPA‑H EVIDENT Support: The trial is funded through the ARPA‑H EVIDENT program (Evidence‑Based Validation & Innovation for Rapid‑Acting Treatments), which aims to accelerate data‑driven behavioral health breakthroughs.
- 72‑Participant Baseline: To isolate core mechanisms, researchers will enroll 72 adults who have no prior experience with psychedelics or formal meditation and who do not have current psychiatric or medical diagnoses.
- Multimodal Biological Assessment: Beyond self‑report measures, the protocol includes EEG, fMRI, blood and saliva analyses, and stool microbiome profiling to provide a comprehensive biological picture.
- Network and Narrative Tracking: Neuroimaging will examine modulation of the brain’s default mode network (DMN) and regions involved in self‑narrative and cognitive control.
- Longitudinal Follow‑Up: Participants will return for structured follow‑up evaluations at three months, six months, and one year to assess the durability of psychological, cognitive, and spiritual changes.
Source: USC
Study Leadership and Collaboration
The trial is led by investigators across USC’s Keck School of Medicine, the Brain and Creativity Institute, and the Norris Comprehensive Cancer Center. Co‑leaders include Rael Cahn, MD, PhD, director of the USC Center for Mindfulness Science and clinical associate professor of psychiatry and behavioral sciences, and Caryn Lerman, PhD, director of the USC Norris Comprehensive Cancer Center and Distinguished Professor of Psychiatry and Behavioral Sciences. The study will be conducted at the USC Brain and Creativity Institute with collaboration from researchers specializing in cognitive neuroimaging, music and brain interactions, and psychology.
Psilocybin and mental health
Psilocybin is a naturally occurring psychedelic compound that can profoundly alter perception, mood, and cognition. With careful therapeutic support, psilocybin experiences can produce emotionally meaningful, potentially transformative states. The U.S. Food and Drug Administration has recognized psilocybin with a breakthrough therapy designation for major depressive disorder and treatment‑resistant depression, and early studies also suggest promise for addiction treatment.
Study leaders note that psilocybin-assisted therapy could change how researchers and clinicians approach mental health by enabling rapid shifts in entrenched cognitive and emotional patterns. The current trial is designed to rigorously evaluate that potential while contributing high‑quality data to a broader national research effort.
Participants will be randomized to receive supervised psilocybin-assisted therapy either alone or alongside an eight‑week mindfulness meditation program. Mindfulness training — a structured set of practices aimed at sustaining focused awareness and adaptive attention — has documented benefits for mental and physical health. The working hypothesis is that practicing mindfulness during the heightened neuroplastic window opened by psilocybin will reinforce durable cognitive and behavioral change.
Evaluation with comprehensive data
The open‑label trial will enroll roughly 72 middle‑aged adults without current psychiatric or medical pathology and without prior psychedelic or formal meditation experience. All participants will undergo psilocybin‑assisted therapy sessions as part of a structured protocol at the USC Brain and Creativity Institute. Because the study is open label, both participants and researchers will know the assigned treatment arm.
Assessments include EEG and structural/functional MRI scans, blood and saliva assays, stool microbiome sampling, and a battery of psychological and cognitive tests conducted before and after treatment. Follow‑up assessments at three months, six months, and one year will allow the team to evaluate changes in mood, cognition, spirituality, brain function tied to self‑processing and narrative, and biological markers related to inflammation and neural health.
“Mindfulness meditation gives people practical tools to deconstruct unhelpful narratives,” said Rael Cahn. “When combined with psilocybin, that training may better capture and sustain the brain changes initiated during psychedelic‑assisted therapy.”
About the study
This research is supported by ARPA‑H’s EVIDENT program, which emphasizes detailed, near real‑time clinical data collection to accelerate behavioral health advances. De‑identified data from EVIDENT studies — including biomarker, neuroimaging, and microbiome datasets — are contributed to a secure national repository to enable large‑scale modeling and discovery of biological patterns associated with rapid improvements in mental health. ARPA‑H is part of the U.S. Department of Health and Human Services and funds high‑impact research to improve health outcomes.
Funding: This work was funded in part by the Advanced Research Projects Agency for Health (ARPA‑H). The views expressed are those of the authors and do not necessarily reflect official U.S. Government policy.
Key Questions Answered:
A: Studying healthy volunteers creates a clearer baseline for understanding core brain mechanisms without confounding factors such as active disease, medication, or variable symptom severity. This cleaner biological and behavioral portrait helps researchers map how psilocybin and mindfulness interact, which in turn informs the design of targeted clinical trials for specific disorders.
A: EVIDENT (Evidence‑Based Validation & Innovation for Rapid‑Acting Treatments) is an ARPA‑H program that supports rigorous behavioral health trials and centralized, de‑identified data sharing. Data from this study — including genetic, neuroimaging, and microbiome information — will be contributed to a secure national repository to support cross‑study analyses and the identification of biological signatures tied to rapid mental health recovery.
A: Psilocybin induces a temporary period of increased neuroplasticity when the brain is more open to new patterns. Without targeted practice, people may revert to old cognitive habits as that window closes. Mindfulness provides explicit, repeatable cognitive tools to notice and interrupt unhelpful narratives. Training those skills during the psilocybin‑enhanced window could help consolidate lasting changes in brain wiring and behavior.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this psychedelics and neuroscience research news
Author: Laura LeBlanc
Source: USC
Contact: Laura LeBlanc – USC
Image: The image is credited to Neuroscience News